Supplementary Figure 5 from Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model

ERBB3 levels are significantly higher following co-treatment with letrozole and everolimus